Thrombopoietin receptor agonist

Lusutrombopag

Brand names: Mulpleo

Lusutrombopag is an oral thrombopoietin receptor agonist used to treat severe thrombocytopenia in adults with chronic liver disease who are undergoing a planned invasive procedure.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds the thrombopoietin receptor on megakaryocyte precursors and stimulates their proliferation and differentiation, increasing platelet production.

Prescribing in practice

It increases the risk of thromboembolism, including portal vein thrombosis in patients with chronic liver disease, so assess thrombotic risk before treatment.
It is intended for short-term peri-procedural use rather than ongoing management of chronic thrombocytopenia.
Treatment should be timed in advance of the procedure in line with the SPC.

Monitoring

Monitor the platelet count before the procedure to confirm an adequate response and remain alert for thrombotic complications.

Counselling the patient

This is a short course of tablets taken ahead of your planned procedure.
Seek urgent advice if you develop abdominal pain, breathlessness or limb swelling.

Evidence & guidelines

Its use in chronic liver disease before procedures is supported by the L-PLUS phase 3 trial programme.

Reference: NICE TA617; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale · Neuromuscular

Pathways